The aim of this study was to compare outcomes after transcatheter aortic valve replacement (TAVR) with the Edwards SAPIEN 3 Ultra (Ultra) and SAPIEN 3 (S3) transcatheter heart valves (THVs). The latest generation balloon-expandable Ultra THV incorporates new technical features and might improve outcomes following TAVR. Device success rates were high with both balloon-expandable THVs, with overall low rates of adverse events up to 30 days after TAVR. Despite a lower frequency of predilatation, significant reduction of mild paravalvular leakage confirms improved annular sealing properties of the novel Ultra THV.
«
The aim of this study was to compare outcomes after transcatheter aortic valve replacement (TAVR) with the Edwards SAPIEN 3 Ultra (Ultra) and SAPIEN 3 (S3) transcatheter heart valves (THVs). The latest generation balloon-expandable Ultra THV incorporates new technical features and might improve outcomes following TAVR. Device success rates were high with both balloon-expandable THVs, with overall low rates of adverse events up to 30 days after TAVR. Despite a lower frequency of predilatation, si...
»